Oppenheimer Asset Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-18,276
Closed -$134K – 1202
2025
Q2
$134K Sell
18,276
-12,923
-41% -$104K ﹤0.01% 1132
2025
Q1
$296K Buy
31,199
+927
+3% +$11.6K ﹤0.01% 965
2024
Q4
$499K Sell
30,272
-2,350
-7% -$36.5K 0.01% 861
2024
Q3
$481K Buy
32,622
+117
+0.4% +$1.83K 0.01% 891
2024
Q2
$451K Buy
32,505
+1,030
+3% +$14.6K 0.01% 881
2024
Q1
$495K Buy
31,475
+3,899
+14% +$60.2K 0.01% 839
2023
Q4
$446K Buy
27,576
+7,998
+41% +$131K 0.01% 891
2023
Q3
$241K Buy
19,578
+6,062
+45% +$90.1K ﹤0.01% 1009
2023
Q2
$217K Buy
+13,516
New +$223K ﹤0.01% 1047
2022
Q1
– Sell
-7,262
Closed -$248K – 1234
2021
Q4
$248K Buy
7,262
+26
+0.4% +$1.02K ﹤0.01% 1124
2021
Q3
$349K Sell
7,236
-14,272
-66% -$661K 0.01% 1019
2021
Q2
$972K Sell
21,508
-3,935
-15% -$174K 0.01% 766
2021
Q1
$1.23M Buy
25,443
+287
+1% +$14.9K 0.02% 658
2020
Q4
$1.35M Buy
25,156
+799
+3% +$36.1K 0.02% 590
2020
Q3
$898K Buy
24,357
+5,421
+29% +$202K 0.02% 652
2020
Q2
$586K Buy
18,936
+11,602
+158% +$322K 0.01% 753
2020
Q1
$202K Buy
7,334
+6,398
+684% +$192K 0.01% 967
2019
Q4
$28K Buy
936
+781
+504% +$18.6K ﹤0.01% 1418
2019
Q3
$3K Hold
155
– – ﹤0.01% 1556
2019
Q2
$3K Hold
155
– – ﹤0.01% 1575
2019
Q1
$3K Sell
155
-1,704
-92% -$29.6K ﹤0.01% 1557
2018
Q4
$23K Buy
+1,859
New +$27.7K ﹤0.01% 1453
2017
Q4
– Sell
-5,976
Closed -$67K – 1334
2017
Q3
$67K Buy
5,976
+532
+10% +$5.18K ﹤0.01% 1298
2017
Q2
$49K Buy
5,444
+3,123
+135% +$24.8K ﹤0.01% 1353
2017
Q1
$18K Buy
+2,321
New +$18.9K ﹤0.01% 1487

Other funds holding NEO

Oppenheimer Asset Management's NEO Position: Q3 2025 in Review

Oppenheimer Asset Management sold out of NeoGenomics (NEO) in Q3 2025, closing a stake of 18,276 shares — an estimated $134K sold.

Oppenheimer Asset Management first reported a position in NEO in Q1 2017 and held it in 25 quarters. The position peaked at $1.35M in Q4 2020. 254 funds tracked by Wall St. Rank hold NEO as of Q3 2025.

  • Oppenheimer Asset Management reported no remaining NeoGenomics position as of Q3 2025 after selling out during the quarter.
  • Oppenheimer Asset Management sold 18,276 NeoGenomics shares in Q3 2025, an estimated $134K.
  • Oppenheimer Asset Management first reported a position in NeoGenomics in Q1 2017 and held it in 25 quarters.
  • Oppenheimer Asset Management's NeoGenomics position peaked at $1.35M in Q4 2020.
  • 254 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2025.

Based on Oppenheimer Asset Management's 13F filing for Q3 2025, filed 6 Nov 2025.